These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7743474)

  • 1. Pulmonary metastases from prostate cancer.
    Fabozzi SJ; Schellhammer PF; el-Mahdi AM
    Cancer; 1995 Jun; 75(11):2706-9. PubMed ID: 7743474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of pulmonary metastases in stage D2 prostate cancer patients.
    Nakamachi H; Suzuki H; Akakura K; Imamoto T; Ueda T; Ishihara M; Furuya Y; Ichikawa T; Igarashi T; Ito H
    Prostate Cancer Prostatic Dis; 2002; 5(2):159-63. PubMed ID: 12497007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal manipulation of pulmonary metastases from carcinoma of the prostate.
    Morin ME; MacNealy GA; Tan A; Li YP; Engel G; Henneberry M
    Urol Radiol; 1982; 4(1):23-7. PubMed ID: 7101599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
    Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
    Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.
    Siddiqui K; Abbas F; Biyabani SR; Ather MH; Talati J
    J Pak Med Assoc; 2004 Sep; 54(9):445-7. PubMed ID: 15518364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
    Fukuda M; Takashima H; Fuse H; Hirano S
    Hinyokika Kiyo; 2002 Aug; 48(8):499-502. PubMed ID: 12243078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
    Shou J; Zhang Q; Wang S; Zhang D
    Prostate; 2018 May; 78(7):491-497. PubMed ID: 29436722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
    Heidenreich A; Pfister D; Porres D
    J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
    Behrakis P; Koutsilieris M
    Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.